Skip to content

Study · Non-randomized trial · n = 5 · 2011

4 results

Systemic photoprotection in solar urticaria with α-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-α-MSH.

Haylett AK, Nie Z, Brownrigg M, Taylor R, Rhodes LE

The British journal of dermatology1 Feb 2011Cited by 47 (Europe PMC)

PMID20969564 (opens in a new tab)DOI10.1111/j.1365-2133.2010.10104.x (opens in a new tab)PepBankPUB-20969564
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In five patients with solar urticaria, mean melanin density increased by day 7, peaked at day 15 and remained elevated at day 60 after a single afamelanotide implant.

    In plain wordsIn five people with solar urticaria, one afamelanotide implant raised skin melanin from day 7, peaking at day 15 and staying higher at day 60.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreaseMelanin density
    Study

    n = 5

    Comparator
    Baseline
    Outcome group
    Pigmentation · Skin and wound
    Studied dose
    16 mg · subcutaneous · single implantAs given in this study (human).

    Source sentences

    Summary
    Mean melanin density increased by day 7, peaked at day 15 and remained elevated at day 60 (P=0·03, 0·01, 0·02 vs. baseline, respectively).
    1 context sentence
    Summary · context
    Five patients with solar urticaria received a single dose of 16 mg subcutaneous afamelanotide implant in winter time.
  2. 02HumanNon-randomized trialEfficacy outcome

    In five patients with solar urticaria, afamelanotide gave mean rises in minimum urticarial dose of 1-12 dose increments at 30 days and 1-3 at 60 days at the individual wavelengths tested.

    In plain wordsIn five people with solar urticaria, afamelanotide raised the light dose needed to cause hives at the wavelengths tested, at 30 and 60 days.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreaseMinimum urticarial dose (MUD) rise at individual wavelengths
    Study

    n = 5

    Comparator
    Baseline
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    16 mg · subcutaneous · single implantAs given in this study (human).

    Measurements

    MUD rise
    1 to 12 dose increments
    30 days
    MUD rise
    1 to 3 dose increments
    60 days

    Source sentences

    Summary
    on afamelanotide mean rises in MUD of 1-12 and 1-3 dose increments were seen at the individual wavelengths tested, at 30 and 60 days, respectively.
    1 context sentence
    Summary · context
    Five patients with solar urticaria received a single dose of 16 mg subcutaneous afamelanotide implant in winter time.
  3. 03HumanNon-randomized trialEfficacy outcome

    In five patients with solar urticaria, weal area fell significantly across responding wavelengths from 300 to 600 nm at 60 days after the afamelanotide implant (P=0·049 vs. baseline).

    In plain wordsIn five people with solar urticaria, the size of light-induced wheals fell significantly 60 days after the afamelanotide implant.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseWeal area across responding wavelengths at 60 days
    Study

    n = 5

    Comparator
    Baseline
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    16 mg · subcutaneous · single implantAs given in this study (human).

    Source sentences

    Summary
    A significant fall in weal area occurred across responding wavelengths from 300 to 600 nm at 60 days postimplant (P=0·049 vs. baseline)
    1 context sentence
    Summary · context
    Five patients with solar urticaria received a single dose of 16 mg subcutaneous afamelanotide implant in winter time.
  4. 04HumanNon-randomized trialEfficacy outcome

    In five patients with solar urticaria, afamelanotide was accompanied by a greater than twofold overall increase in minimum urticarial dose at 60 days (P=0·058 vs. baseline).

    In plain wordsIn five people with solar urticaria, the light dose needed to cause hives more than doubled overall at 60 days (P=0·058 versus baseline).

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreaseOverall minimum urticarial dose at 60 days
    Study

    n = 5

    Comparator
    Baseline
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    16 mg · subcutaneous · single implantAs given in this study (human).

    Source sentences

    Summary
    accompanied by greater than twofold overall increase in MUD (P=0·058 vs. baseline).
    1 context sentence
    Summary · context
    Five patients with solar urticaria received a single dose of 16 mg subcutaneous afamelanotide implant in winter time.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.